Gabapentin Capsule
Product Images NDC 50090-6718

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-6718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation Of Cockcroft And Gault (Gabapentin Fig1)

An illustration showing the formula to calculate Creatinine Clearance (CLCr). It includes variables such as age in years, weight in kilograms, serum creatinine levels in mg/dl, and an adjustment factor for female patients (0.85). The formula is used in clinical pharmacokinetics.*

FDA Label Image

Fig-2 (Gabapentin Fig2)

A line graph depicting mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline to 8, and the y-axis shows mean pain scores from 0 to 10. Two phases are noted: a 4-week dose titration period followed by a 4-week fixed dose period. The graph shows a decrease in mean pain score for the Gabapentin group, while the placebo group remains relatively stable.*

FDA Label Image

Fig-3 (Gabapentin Fig3)

A line graph depicting mean pain scores over 7 weeks comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis shows weeks divided into a 3-week dose titration period and a 4-week fixed dose period, while the y-axis represents mean pain scores from 0 to 10. Gabapentin groups show lower pain scores over time compared to placebo.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and various doses of Gabapentin (GBP) in two studies. Study 1 shows 12% for placebo and 29% for Gabapentin 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for Gabapentin 1800 mg and 2400 mg, respectively. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot showing percentage difference on the y-axis versus daily dose in milligrams on the x-axis. Data points represent results from three different studies labeled as STUDY a, STUDY b, and STUDY c. Each study is depicted with distinct square markers, with study a in dark squares, study b in shaded squares, and study c in light squares. The dose levels range approximately from 600 mg to 1800 mg.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin, showing a cyclohexane ring with an aminomethyl group (CH2NH2) and a carboxymethyl group (CH2CO2H) attached to the same carbon.*

FDA Label Image

Label Image (Lbl500906718)

Gabapentin 300 mg capsules label from A-S Medication Solutions. The label shows the drug name Gabapentin with a strength of 300 mg per capsule. It states storage instructions to store at 68 to 77 degrees Fahrenheit and indicates a package quantity of 90 capsules. The label includes the product NDC 50090-6718-0 and packaging details that the product is from Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.